Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Solomon, B. [1 ]
Bang, Y. J. [2 ]
Camidge, D. R. [3 ]
Iafrate, A. J. [4 ]
Kwak, E. L.
Maki, R. G. [5 ]
Ou, S. I. [6 ]
Salgia, R. [7 ]
Shaw, A.
Clark, J.
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Australia
[2] Seoul Natl Univ, Dept Internal Med, Seoul, South Korea
[3] Univ Colorado, Ctr Canc, Div Med Oncol, Aurora, CO USA
[4] Massachusetts Gen Hosp, Translat Res Lab, Boston, MA 02114 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[6] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA
[7] Univ Chicago, Ctr Canc, Hematol Oncol Sect, Chicago, IL 60637 USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72076-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：117 / 117
页数：1
相关论文
共 50 条
  • [1] CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066), IN ALK-POSITIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Camidge, D. R.
    Bang, Y.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Solomon, B.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 123 - 123
  • [2] PHASE 2 DATA FOR CRIZOTINIB (PF-02341066) IN ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PROFILE 1005
    Riely, Gregory J.
    Kim, Dong-Wan
    Crino, Lucio
    Janne, Pasi A.
    Blackhall, Fiona H.
    Camidge, David R.
    Hirsh, Vera
    Mok, Tony S. K.
    Solomon, Ben
    Soria, Jean-Charles
    Park, Keunchil
    Gadgeel, Shirish M.
    Martins, Renato G.
    Han, Ji-Youn
    De Pas, Tommaso
    Bottomley, Andrew
    Polli, Anna
    Petersen, Jennifer A.
    Tassell, Vanessa R.
    Shaw, Alice T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S411 - S412
  • [3] Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors
    Li, C.
    Alvey, C.
    Bello, A.
    Wilner, K. D.
    Tan, W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC)
    Bang, Y.
    Kwak, E. L.
    Shaw, A. T.
    Camidge, D. R.
    Iafrate, A. J.
    Maki, R. G.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Clark, J. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [5] PROFILE 1005: PRELIMINARY PATIENT-REPORTED OUTCOMES (PROS) FROM AN ONGOING PHASE 2 STUDY OF CRIZOTINIB (PF-02341066) IN ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Blackhall, Fiona H.
    Petersen, Jennifer A.
    Wilner, Keith
    Hirsh, Vera
    Shaw, Alice T.
    Kim, Dong-Wan
    Solomon, Ben
    Janne, Pasi A.
    Reisman, Arlene L.
    Polli, Anna
    Mundayat, Rajiv
    Bottomley, Andrew
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S413 - S414
  • [6] VISUAL DISTURBANCES IN PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH CRIZOTINIB
    Besse, B.
    Salgia, R.
    Solomon, B.
    Shaw, A.
    Kim, D.
    Schachar, R.
    Wilner, K.
    Reisman, A.
    Bartlett, C. H.
    Iyer, S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 416 - 416
  • [7] Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.
    Salgia, Ravi
    Solomon, Benjamin J.
    Shaw, Alice Tsang
    Camidge, D. Ross
    Evans, Tracey L.
    Kim, Dong-Wan
    Shi, Yuankai
    Han, Ji-Youn
    De Pas, Tommaso Martino
    Ou, Sai-Hong Ignatius
    Bartlett, Cynthia Huang
    Wilner, Keith D.
    Reisman, Arlene
    Iyer, Shrividya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).
    Camidge, D. R.
    Bang, Y.
    Kwak, E. L.
    Shaw, A. T.
    Iafrate, A. J.
    Maki, R. G.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Wilner, K. D.
    Costa, D. B.
    Shapiro, G.
    LoRusso, P.
    Stephenson, P.
    Tang, Y.
    Ruffner, K.
    Clark, J. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] VISUAL EFFECTS IN ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH CRIZOTINIB
    Yang, P. -C.
    Salgia, R.
    Solomon, B.
    Shaw, A. T.
    Camidge, D. R.
    Evans, T. L.
    Kim, D. -W.
    Shi, Y.
    Han, J. -Y.
    De Pas, T. M.
    Ou, S. -H. I.
    Bartlett, C. H.
    Wilner, K.
    Reisman, A.
    Iyer, S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 44 - 44
  • [10] Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Choi, Briana
    Alkhatib, Nimer S.
    Pae, Elizabeth
    Babiker, Hani M.
    Garland, Linda L.
    Henglefelt, Alyssa
    McBride, Ali
    Abraham, Ivo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345